Detalhe da pesquisa
1.
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
Lancet Oncol
; 22(6): 813-823, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34000245
2.
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Acta Neuropathol
; 141(6): 945-957, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33740099
3.
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
Lancet Oncol
; 19(9): 1170-1179, 2018 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30115593
4.
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Lancet
; 390(10103): 1645-1653, 2017 Oct 07.
Artigo
Inglês
| MEDLINE | ID: mdl-28801186
5.
Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).
Oncologist
; 23(5): 524-e44, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29472310
6.
Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire.
Health Qual Life Outcomes
; 16(1): 114, 2018 Jun 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29866185
7.
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
N Engl J Med
; 370(8): 709-22, 2014 Feb 20.
Artigo
Inglês
| MEDLINE | ID: mdl-24552318
8.
Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
Eur J Cancer
; 198: 113475, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38159337
9.
Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network.
Neurooncol Adv
; 6(1): vdae078, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38855053
10.
Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.
Curr Neurol Neurosci Rep
; 13(5): 347, 2013 May.
Artigo
Inglês
| MEDLINE | ID: mdl-23529375
11.
Bevacizumab for newly diagnosed glioblastoma.
N Engl J Med
; 370(21): 2049, 2014 05 22.
Artigo
Inglês
| MEDLINE | ID: mdl-24860870
12.
Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial.
Clin Cancer Res
; 28(11): 2440-2448, 2022 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35294545
13.
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Clin Cancer Res
; 28(12): 2527-2535, 2022 06 13.
Artigo
Inglês
| MEDLINE | ID: mdl-35275197
14.
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
Neuro Oncol
; 23(9): 1547-1559, 2021 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33914057
15.
Cilengitide in glioblastoma: when did it fail?
Lancet Oncol
; 15(10): 1044-5, 2014 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-25163907
16.
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Cancer Treat Rev
; 86: 102017, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32335505
17.
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.
Clin Cancer Res
; 25(6): 1809-1816, 2019 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30514777
18.
Corrigendum to "Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial" [Eur J Cancer 198 (2024) 113475].
Eur J Cancer
; 204: 114066, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38658199
19.
A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study.
Neuro Oncol
; 21(8): 1039-1048, 2019 08 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31102405
20.
Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.
Oncotarget
; 9(6): 6752-6762, 2018 Jan 23.
Artigo
Inglês
| MEDLINE | ID: mdl-29467925